Comparative study in the expression of p53, EGFR, TGF-α, and cyclin D1 in verrucous carcinoma, verrucous hyperplasia, and squamous cell carcinoma of head and neck region

Applied Immunohistochemistry and Molecular Morphology

Volumn 10, Issue 4, 2002, Pages 351-356

  Wu, Maoxin ^a   Putti, Thomas C ^b   Bhuiya, Tawfiqul A ^b  

^a MOUNT SINAI HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cyclin D1; Epidermal growth factor receptor; p53; Squamous cell carcinoma; Transforming growth factor ; Verrucous carcinoma; Verrucous hyperplasia

Indexed keywords

AVIDIN; BIOTIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; COMPARATIVE STUDY; CORRELATION ANALYSIS; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; TUMOR DIFFERENTIATION; VERRUCOUS CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CARCINOMA, VERRUCOUS; CELL DIFFERENTIATION; CYCLIN D1; EPITHELIUM; HEAD AND NECK NEOPLASMS; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036899910     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: 10.1097/00022744-200212000-00011     Document Type: Article

References (34)

1. Ackerman LV. Verrucous carcinoma of the oral cavity. Surgery 1948:23:670-8.
2. Kraus FT, Perez-Mesa C. Verrucous carcinoma. Clinical and pathologic study of 105 cases involving oral cavity, larynx and genitalia. Cancer 1966;19:26-38.
3. Jacobson S, Shear M. Verrucous carcinoma of the mouth. J Oral Pathol 1972;1:66.
4. McCoy JM, Waldron CA. Verrucous carcinoma of the oral cavity. A review of forty nine cases. Oral Surg 1981;52:623.
5. Batsakis JG, Hybels R, Crissman JD, et al. The pathology of head and neck tumors; verrucous carcinoma. Head Neck Surg 1982;5: 29-38.
6. Jesus EM, Dichtel MW, Luna MA. Verrucous-squamous carcinomas of the oral cavity. A clinicopathologic study of 104 cases. Arch Otolaryngol 1984;110:437-40.
7. Slootweg PJ. Muller H. Verrucous hyperplasia or verrucous carcinoma. An analysis of 27 patients. J Maxillofac Surg 1983;11: 13-9.
8. Shear M. Pindborg JJ. Verrucous hyperplasia of the oral mucosa. Cancer 1980;46:1855-62.
9. Hansen LS. Olson JA, Silverman S Jr. Proliferative verrucous leukoplakia. A long-term study of thirty patients. Oral Surg Med Oral Pathol 1985;60:285-98.
10. John JR, Evan G, Bruce RL, et al. Expression of p53. TGF-alpha, EGFR and C-erbB2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 1984;25: 1075-83.
11. Urs W, Guido S, Holger M, et al. Patterns of p53, erbB2 and EGFR expression in premalignant lesions of urinary bladder. Hum Pathol 1995;26:970-8.
12. Kearsley JH, Furlong RA, Cooke. et al. An immunochemical assessment of cellular proliferation markers in head and neck squamous cell cancers. Br J Cancer 1990;61:821-7.
13. Rusch V, Klimstra D. Linkov I, et al. Aberrant expression of p53 or the EGFR is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res 1995;55:1365-72.
14. Gimenez-Conti IB, Collet AM, Lanfranchi H, et al. P53, Rb, and Cyclin D-1 expression in human oral verrucous carcinomas. Cancer 1996;78:17-23.
15. Chang F, et al. The p53 tumor suppresser gene as a common cellular target in human carcinogenesis. Am J Gastroenterol 1993; 88:174.
16. Frebourg T, Friend SH. Cancer risks from germline p53 mutations. J Clin Invest 1192;90:1637.
17. Porter PL, Gown AM, Kramp SG, et al. Widespread p53 overexpression in human malignant tumors. Am J Pathol 1992;140: 145-53.
18. Ozanne B, Richards CS, Hendler F, et al. Overexpression of EGF receptor is a hallmark of squamous cell carcinomas. J Pathol 1986: 149:9-14.
19. Carpenter G, Zendegui JG. Epidermal growth factor, its receptor and related proteins. Exp Cell Res 1986;164:1-10.
20. Gullick WJ. Prevalence of aberrant expression of the EGF receptors in human cancers. Br Med Bull 1991;47:87.
21. Burgess AW. EGF and TGF alpha. Br Med Bull 1989;45:401-24.
22. Salomon DS, Kim N, Saeki T, et al. TGF alpha: An onco developmental growth factor. Cancer Cell 1990;2:389-97.
23. Derynck R. TGF alpha. Cell 1988;54:593-5.
24. Dimarco E, Pierce JH, Fleming TP, et al. Autocrine interaction between TGF alpha and EGF receptor: Quantitative requirements for induction of the malignant phenotype. Oncogene 1989;4: 831-8.
25. Motokura T, Arnold A. Cyclins and oncogenesis. Biochim Biophys Acta 1993;155:63-78.
26. Lammie GA, Fanti V, Smith R, et al. D11S287, a putative oncogene on chromosome 11q13 is amplified and expressed in squamous cell and mammary carcinomas linked to BCWL-1. Oncogene 1991;6:439-44.
27. Jiang W, Zhang YJ, Kahn SM, et al. Altered expression of the cyclin D-1 and the retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci U S A 1993;90:9026-30.
28. Vogelstein B, Kinzler KW. P53 function and dysfunction. Cell 1992;70:523-6.
29. Cattoretti G, Rilke F, Andreola S, et al. P53 expression in breast cancer. Int J Cancer 1988;41:178-83.
30. Rady P, Scinicariello F, Wagner RF Jr, et al. P53 mutations in basal cell carcinomas. Cancer Res 1992;52:3804-6.
31. Eisbruch A, Blick M, Lee JS, et al. Analysis of epidermal growth factor receptor gene in fresh human head and neck tumors. Cancer Res 1987;47:3603-5.
32. Hendler FJ, Ozanne BW. Human squamous cell lung cancer express increase of epidermal growth factor receptors. J Clin Invest 1984;74:647-51.
33. Shin DM, Ro JY, Hong WK, et al. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis, Cancer Res 1994;54:3153-9.
34. Callender T, el-Naggar AK, Lee MS, et al. PRAD-1 (CCNDI)/Cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer 1994;74:152.